Takeda unveils robust pipeline, adjusts FY2025 financial outlook

Takeda's fiscal year 2025 interim report details the advancement of six late-stage pipeline programs, including positive Phase 3 data for rusfertide and oveporexton, with regulatory submissions planned by year-end. Zasocitinib is also expected to have Phase 3 readouts for psoriasis before the end of the fiscal year. These programs collectively represent a peak revenue potential of between $10 and $20 bn. A global strategic partnership further strengthens Takeda’s R&D pipeline with two late-stage oncology assets and an early-stage program option.

For the first half of fiscal year 2025, Takeda reported 2,219.5 bn yen in revenue. Growth & Launch Products achieved 1,143.0 bn yen, a 5.3% increase at constant exchange rate (CER). Key growth drivers include ENTYVIO (GI, +5.1% CER) and LIVTENCITY (Rare Diseases, +47.7% CER). However, the neuroscience segment saw a 32.1% decline at CER, primarily due to the loss of exclusivity for VYVANSE in the U.S.

Takeda has revised its full-year forecast and management guidance for Core Operating Profit and Core EPS. These adjustments reflect reduced sales forecasts for products like ENTYVIO and VYVANSE, impairment losses on intangible assets, transactional FX headwinds, and a higher tax rate, partially offset by savings from OPEX management.